ES2797650T3 - Administración de lípido eficiente a película lagrimal humana usando un sistema de emulsión sensible a sal - Google Patents
Administración de lípido eficiente a película lagrimal humana usando un sistema de emulsión sensible a sal Download PDFInfo
- Publication number
- ES2797650T3 ES2797650T3 ES12808606T ES12808606T ES2797650T3 ES 2797650 T3 ES2797650 T3 ES 2797650T3 ES 12808606 T ES12808606 T ES 12808606T ES 12808606 T ES12808606 T ES 12808606T ES 2797650 T3 ES2797650 T3 ES 2797650T3
- Authority
- ES
- Spain
- Prior art keywords
- concentration
- salt
- pharmaceutical composition
- ophthalmic pharmaceutical
- low
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 127
- 150000002632 lipids Chemical class 0.000 title claims abstract description 84
- 239000000839 emulsion Substances 0.000 title claims abstract description 49
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 84
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 41
- 229920000642 polymer Polymers 0.000 claims abstract description 34
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims abstract description 25
- 239000004094 surface-active agent Substances 0.000 claims abstract description 20
- -1 sorbitan ester Chemical class 0.000 claims abstract description 16
- 239000004359 castor oil Substances 0.000 claims abstract description 15
- 235000019438 castor oil Nutrition 0.000 claims abstract description 15
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract description 15
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 13
- 229920006037 cross link polymer Polymers 0.000 claims abstract description 13
- 239000000314 lubricant Substances 0.000 claims abstract description 13
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 12
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 16
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 10
- 239000004386 Erythritol Substances 0.000 claims description 10
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 10
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical group OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 10
- 235000019414 erythritol Nutrition 0.000 claims description 10
- 229940009714 erythritol Drugs 0.000 claims description 10
- 229960001518 levocarnitine Drugs 0.000 claims description 10
- 125000005430 oxychloro group Chemical group 0.000 claims description 9
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 9
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 9
- 229920000053 polysorbate 80 Polymers 0.000 claims description 9
- 229940068968 polysorbate 80 Drugs 0.000 claims description 9
- 239000003755 preservative agent Substances 0.000 claims description 9
- 235000011187 glycerol Nutrition 0.000 claims description 8
- 230000002335 preservative effect Effects 0.000 claims description 8
- 239000004327 boric acid Substances 0.000 claims description 6
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 4
- 238000010998 test method Methods 0.000 claims description 3
- 235000002639 sodium chloride Nutrition 0.000 description 131
- 239000000203 mixture Substances 0.000 description 46
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 33
- 238000000034 method Methods 0.000 description 30
- 239000012071 phase Substances 0.000 description 25
- 239000000523 sample Substances 0.000 description 18
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 17
- 206010013774 Dry eye Diseases 0.000 description 17
- 230000005540 biological transmission Effects 0.000 description 17
- 238000010790 dilution Methods 0.000 description 17
- 239000012895 dilution Substances 0.000 description 17
- 239000011780 sodium chloride Substances 0.000 description 17
- 230000008859 change Effects 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 238000011282 treatment Methods 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 9
- 239000003889 eye drop Substances 0.000 description 9
- 239000008346 aqueous phase Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 6
- 229940012356 eye drops Drugs 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000003002 pH adjusting agent Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000012929 tonicity agent Substances 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000001687 destabilization Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000003974 emollient agent Substances 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000004175 meibomian gland Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 125000005619 boric acid group Chemical group 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 239000013026 undiluted sample Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010065062 Meibomian gland dysfunction Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000005188 flotation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- KUQWZSZYIQGTHT-UHFFFAOYSA-N hexa-1,5-diene-3,4-diol Chemical compound C=CC(O)C(O)C=C KUQWZSZYIQGTHT-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 231100001032 irritation of the eye Toxicity 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000000065 osmolyte Effects 0.000 description 1
- 230000001033 osmoprotective effect Effects 0.000 description 1
- 230000008723 osmotic stress Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000003236 psychic effect Effects 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 208000005494 xerophthalmia Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161568089P | 2011-12-07 | 2011-12-07 | |
| US201261625401P | 2012-04-17 | 2012-04-17 | |
| PCT/US2012/068603 WO2013086438A1 (en) | 2011-12-07 | 2012-12-07 | Efficient lipid delivery to human tear film using a salt-sensitive emulsion system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2797650T3 true ES2797650T3 (es) | 2020-12-03 |
Family
ID=47459152
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12808607T Active ES2896336T3 (es) | 2011-12-07 | 2012-12-07 | Suministro eficiente de lípidos a película lagrimal humana usando un sistema de emulsión sensible a sales |
| ES12808606T Active ES2797650T3 (es) | 2011-12-07 | 2012-12-07 | Administración de lípido eficiente a película lagrimal humana usando un sistema de emulsión sensible a sal |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12808607T Active ES2896336T3 (es) | 2011-12-07 | 2012-12-07 | Suministro eficiente de lípidos a película lagrimal humana usando un sistema de emulsión sensible a sales |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20130150324A1 (enExample) |
| EP (5) | EP3666257A1 (enExample) |
| JP (1) | JP6142419B2 (enExample) |
| KR (1) | KR102017922B1 (enExample) |
| CN (2) | CN104114152A (enExample) |
| AR (1) | AR089123A1 (enExample) |
| AU (2) | AU2012347459A1 (enExample) |
| BR (1) | BR112014013820A8 (enExample) |
| CA (1) | CA2858574C (enExample) |
| CL (1) | CL2014001518A1 (enExample) |
| CO (1) | CO6990739A2 (enExample) |
| DK (2) | DK2787968T3 (enExample) |
| ES (2) | ES2896336T3 (enExample) |
| HU (2) | HUE057140T2 (enExample) |
| IL (1) | IL233008A (enExample) |
| IN (1) | IN2014CN04809A (enExample) |
| MX (1) | MX355216B (enExample) |
| MY (1) | MY173378A (enExample) |
| PH (2) | PH12021553172A1 (enExample) |
| PL (2) | PL2787968T3 (enExample) |
| PT (2) | PT2787969T (enExample) |
| RU (1) | RU2014127074A (enExample) |
| SG (1) | SG11201403013VA (enExample) |
| SI (2) | SI2787969T1 (enExample) |
| TW (1) | TWI652072B (enExample) |
| WO (2) | WO2013086449A1 (enExample) |
| ZA (1) | ZA201404228B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8957048B2 (en) * | 2011-10-06 | 2015-02-17 | Allergan, Inc. | Compositions for the treatment of dry eye |
| US9907826B2 (en) | 2011-12-07 | 2018-03-06 | Allergan, Inc. | Efficient lipid delivery to human tear film using a salt-sensitive emulsion system |
| PT3266446T (pt) | 2016-07-07 | 2019-01-30 | Salvat Lab Sa | Composição oftálmica compreendendo óleo de rícino e triglicérido de cadeia média |
| WO2018035469A1 (en) | 2016-08-19 | 2018-02-22 | Akrivista, LLC | Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye |
| WO2019036625A1 (en) | 2017-08-18 | 2019-02-21 | Akrivista, LLC | METHODS FOR DIAGNOSING AND TREATING DRY-LIKE SYNDROME AND COMPOSITIONS FOR TREATING A HUMAN EYE |
| EP3784354A1 (en) | 2018-04-27 | 2021-03-03 | Allergan, Inc. | Sodium chlorite compositions with enhanced anti-microbial efficacy and reduced toxicity |
| WO2025175150A1 (en) * | 2024-02-16 | 2025-08-21 | Allergan, Inc. | Enhanced artificial tear formulations |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4201706A (en) | 1978-09-22 | 1980-05-06 | Burton, Parsons & Company, Inc. | Treatment of corneal edema |
| DE3066859D1 (en) * | 1979-10-26 | 1984-04-12 | Smith & Nephew Ass | Autoclavable emulsions |
| US5192535A (en) | 1988-02-08 | 1993-03-09 | Insite Vision Incorporated | Ophthalmic suspensions |
| IT1224795B (it) | 1988-12-01 | 1990-10-24 | Sigma Tau Ind Farmaceuti | Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento |
| DK0436726T3 (da) | 1989-08-03 | 1993-12-27 | Eisai Co Ltd | Fotostabil oftalmisk opløsning og fremgangsmåde til fremstilling deraf |
| US5681555A (en) | 1991-04-22 | 1997-10-28 | Gleich; Gerald J. | Method for the treatment of bronchial asthma by parenteral administration of anionic polymers |
| DE4229494A1 (de) | 1992-09-04 | 1994-03-10 | Basotherm Gmbh | Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks |
| AU3484895A (en) | 1994-09-14 | 1996-03-29 | Taisho Pharmaceutical Co., Ltd. | Eye drops for repairing corneal disturbance |
| US5980865A (en) | 1995-08-18 | 1999-11-09 | Baker Norton Pharmaceuticals, Inc. | Method for treating late phase allergic reactions and inflammatory diseases |
| FI106923B (fi) | 1997-01-03 | 2001-05-15 | Cultor Ltd Finnsugar Bioproduc | Trimetyyliglysiinin käyttö kehon limakalvojen hygieniaan ja hoitoon tarkoitetuissa valmisteissa |
| AR002194A1 (es) | 1997-03-17 | 1998-01-07 | Sanchez Reynaldo Alemany | Instrumento computarizado para el analisis del movimiento. |
| IT1302307B1 (it) | 1998-09-01 | 2000-09-05 | Sigma Tau Healthscience Spa | Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil |
| AU1295200A (en) | 1998-11-13 | 2000-06-05 | Continental Projects Limited | Complexes of hyaluronic acid/carnitines and pharmaceutical and cosmetic compositions |
| JP2000159659A (ja) * | 1998-11-30 | 2000-06-13 | Kazuo Tsubota | 眼科用人工涙液 |
| US6228392B1 (en) | 1999-04-29 | 2001-05-08 | Gene Tools, Llc | Osmotic delivery composition, solution, and method |
| CN1441679A (zh) | 2000-07-14 | 2003-09-10 | 阿勒根公司 | 包含具有提高的溶解度的治疗活性组分的组合物 |
| CA2355814C (en) | 2000-09-14 | 2010-06-29 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Pharmaceutical composition for ophthalmic use |
| DK1339418T3 (da) | 2000-11-08 | 2009-12-14 | Fxs Ventures Llc | Forbedret ophthalmiske og kontaktlinseoplösninger indeholdende simple saccharider som konserverende forstærkere |
| US7045121B2 (en) | 2001-12-14 | 2006-05-16 | Allergan, Inc. | Ophthalmic compositions for lubricating eyes and methods for making and using same |
| JP2006504701A (ja) | 2002-09-30 | 2006-02-09 | マーク・エー・バビザイェフ | 眼疾患の局所的治療方法、並びに、その治療用組成物及び治療用手段 |
| ES2314284T3 (es) * | 2002-10-18 | 2009-03-16 | Aqueous Pharma Limited | Formulacion lagrimal de tres capas. |
| US20040137079A1 (en) | 2003-01-08 | 2004-07-15 | Cook James N. | Contact lens and eye drop rewetter compositions and methods |
| US6635654B1 (en) * | 2003-01-09 | 2003-10-21 | Allergan, Inc. | Ophthalmic compositions containing loratadine |
| US20040185068A1 (en) * | 2003-03-18 | 2004-09-23 | Zhi-Jian Yu | Self-emulsifying compositions, methods of use and preparation |
| WO2004084877A1 (ja) | 2003-03-26 | 2004-10-07 | Menicon Co., Ltd. | 眼科用組成物 |
| CA2839930C (en) * | 2003-06-13 | 2016-07-05 | Alcon, Inc. | Ophthalmic compositions containing a synergistic combination of two polymers |
| TWI336257B (en) * | 2003-06-13 | 2011-01-21 | Alcon Inc | Ophthalmic compositions containing a synergistic combination of three polymers |
| US20050009836A1 (en) | 2003-06-26 | 2005-01-13 | Laskar Paul A. | Ophthalmic composition containing quinolones and method of use |
| KR20060121151A (ko) * | 2003-11-10 | 2006-11-28 | 도레이 가부시끼가이샤 | 다당류 함유 조성물 및 누액층 안정화 점안제 |
| US8569367B2 (en) * | 2004-11-16 | 2013-10-29 | Allergan, Inc. | Ophthalmic compositions and methods for treating eyes |
| US7288520B2 (en) * | 2005-07-13 | 2007-10-30 | Allergan, Inc. | Cyclosporin compositions |
| US7501393B2 (en) * | 2005-07-27 | 2009-03-10 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
| US9561178B2 (en) * | 2006-07-25 | 2017-02-07 | Allergan, Inc. | Cyclosporin compositions |
| WO2008035246A2 (en) * | 2006-07-28 | 2008-03-27 | Novagali Pharma Sa | Compositions containing quaternary ammonium compounds |
| CN101896160A (zh) * | 2006-10-17 | 2010-11-24 | 阿勒根公司 | 环胞菌素组合物 |
| US20080312194A1 (en) * | 2007-02-28 | 2008-12-18 | Ousler Iii George W | Methods and compositions for normalizing meibomian gland secretions |
| JP4929245B2 (ja) | 2008-07-31 | 2012-05-09 | 株式会社ベッセル工業 | 工具類のグリップ |
| HRP20171691T1 (hr) * | 2009-06-05 | 2017-12-15 | Allergan, Inc. | Umjetne suze i njihova upotreba u terapiji |
| WO2013049621A1 (en) * | 2011-09-29 | 2013-04-04 | The Board Of Regents Of The University Of Oklahoma | Ophthalmic compositions comprising ppar-alpha agonists and methods of production and use thereof |
| US8957048B2 (en) * | 2011-10-06 | 2015-02-17 | Allergan, Inc. | Compositions for the treatment of dry eye |
-
2012
- 2012-12-07 HU HUE12808607A patent/HUE057140T2/hu unknown
- 2012-12-07 DK DK12808606.3T patent/DK2787968T3/da active
- 2012-12-07 WO PCT/US2012/068615 patent/WO2013086449A1/en not_active Ceased
- 2012-12-07 EP EP20153344.5A patent/EP3666257A1/en not_active Withdrawn
- 2012-12-07 PT PT128086071T patent/PT2787969T/pt unknown
- 2012-12-07 US US13/708,783 patent/US20130150324A1/en not_active Abandoned
- 2012-12-07 EP EP12808606.3A patent/EP2787968B1/en active Active
- 2012-12-07 PH PH1/2021/553172A patent/PH12021553172A1/en unknown
- 2012-12-07 SG SG11201403013VA patent/SG11201403013VA/en unknown
- 2012-12-07 WO PCT/US2012/068603 patent/WO2013086438A1/en not_active Ceased
- 2012-12-07 MY MYPI2014001672A patent/MY173378A/en unknown
- 2012-12-07 TW TW101146304A patent/TWI652072B/zh active
- 2012-12-07 CN CN201280067685.0A patent/CN104114152A/zh active Pending
- 2012-12-07 DK DK12808607.1T patent/DK2787969T3/da active
- 2012-12-07 RU RU2014127074A patent/RU2014127074A/ru unknown
- 2012-12-07 PH PH1/2014/501296A patent/PH12014501296B1/en unknown
- 2012-12-07 KR KR1020147018598A patent/KR102017922B1/ko not_active Expired - Fee Related
- 2012-12-07 AR ARP120104614A patent/AR089123A1/es not_active Application Discontinuation
- 2012-12-07 EP EP21198843.1A patent/EP3981387A1/en active Pending
- 2012-12-07 EP EP12808607.1A patent/EP2787969B1/en active Active
- 2012-12-07 ES ES12808607T patent/ES2896336T3/es active Active
- 2012-12-07 HU HUE12808606A patent/HUE049489T2/hu unknown
- 2012-12-07 MX MX2014006804A patent/MX355216B/es active IP Right Grant
- 2012-12-07 SI SI201231957T patent/SI2787969T1/sl unknown
- 2012-12-07 PL PL12808606T patent/PL2787968T3/pl unknown
- 2012-12-07 PT PT128086063T patent/PT2787968T/pt unknown
- 2012-12-07 US US13/708,771 patent/US9314528B2/en active Active
- 2012-12-07 BR BR112014013820A patent/BR112014013820A8/pt not_active Application Discontinuation
- 2012-12-07 CA CA2858574A patent/CA2858574C/en active Active
- 2012-12-07 JP JP2014546154A patent/JP6142419B2/ja active Active
- 2012-12-07 AU AU2012347459A patent/AU2012347459A1/en not_active Abandoned
- 2012-12-07 CN CN201810890387.0A patent/CN108969482A/zh active Pending
- 2012-12-07 IN IN4809CHN2014 patent/IN2014CN04809A/en unknown
- 2012-12-07 ES ES12808606T patent/ES2797650T3/es active Active
- 2012-12-07 EP EP24167560.2A patent/EP4403220A3/en active Pending
- 2012-12-07 SI SI201231783T patent/SI2787968T1/sl unknown
- 2012-12-07 PL PL12808607T patent/PL2787969T3/pl unknown
-
2014
- 2014-06-08 IL IL233008A patent/IL233008A/en active IP Right Grant
- 2014-06-09 CL CL2014001518A patent/CL2014001518A1/es unknown
- 2014-06-09 ZA ZA2014/04228A patent/ZA201404228B/en unknown
- 2014-06-26 CO CO14138315A patent/CO6990739A2/es unknown
-
2017
- 2017-11-27 AU AU2017265181A patent/AU2017265181B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2797650T3 (es) | Administración de lípido eficiente a película lagrimal humana usando un sistema de emulsión sensible a sal | |
| CN102355889B (zh) | 基于多不饱和ω-3和ω-6脂肪酸的眼用组合物 | |
| ES2965828T3 (es) | Composiciones de alcano semifluorado | |
| Ammar et al. | Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride | |
| ES2974663T3 (es) | Alcanos semifluorados para uso en la solubilización de meibomio | |
| US8530449B2 (en) | Composition for a topical ophthalmic clear colloidal liquid which undergoes a liquid-gel phase transition in the eye | |
| US20240293491A1 (en) | Efficient lipid delivery to human tear film using a salt-sensitive emulsion system | |
| ES2638868T3 (es) | Emulsión lacrimomimética | |
| Robciuc et al. | Pure glaucoma drugs are toxic to immortalized human corneal epithelial cells, but they do not destabilize lipid membranes | |
| ES2704918T3 (es) | Composición oftálmica estable en almacenamiento | |
| WO2011006079A2 (en) | Ophthalmic formulations of reversed liquid crystalline phase materials and methods of using | |
| BR112021011210A2 (pt) | Formulações oftálmicas que proporcionam lubrificação ocular durável | |
| EP3893887A1 (en) | Lxr agonist in topical ophthalmic formulation for treatment of dry-eye disorder | |
| BR112020014710A2 (pt) | Emulsão oftálmica à base de lipídio | |
| ES2731151T3 (es) | Composiciones oftálmicas basadas en ácidos poliinsaturados y triacilgliceroles | |
| HK40032380A (en) | Efficient lipid delivery to human tear film using a salt-sensitive emulsion system | |
| US20110177169A1 (en) | Ophthalmic formulations of reversed liquid crystalline phase materials and methods of using | |
| HK1201458B (en) | Efficient lipid delivery to human tear film using a salt-sensitive emulsion system | |
| US20260000725A1 (en) | Efficient lipid delivery to human tear film using a salt-sensitive emulsion system | |
| WO2021045606A1 (es) | Composición farmacéutica oftálmica, procesos de preparación y usos de las mismas | |
| Fawzia et al. | Ocular drug deliver and the importance of microemulsion as a potential delivery system | |
| HK1166714B (en) | Ophthalmic compositions based on polyunsaturated omega-3 and omega-6 fatty acids | |
| TR201603173A1 (tr) | Oftalmi̇k farmasöti̇k bi̇leşi̇mler |